Brain-controlled robotic mirror therapy for arm weakness after stroke
Tests a brain-computer interface robot with mirror therapy for arm movement after stroke.
Plain-language title generated from the registry record
Registry title: Prospective, Randomized, Parallel-Controlled Study of Brain Computer Interface Integrated Robotic Mirror Therapy for Post-Stroke Upper Limb Motor Function Disorder
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 30 to 80 who have weakness in one arm and hand 1 to 6 months after a first stroke. The stroke must be limited to one side of the brain, in the basal ganglia.
- Age
- 30 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Weakness in one upper limb caused by a first ischemic or hemorrhagic stroke 1 to 6 months before joining. The stroke lesion on brain MRI must be limited to the basal ganglia on one side. Fugl-Meyer upper limb score 10 to 42.
Main reasons for not taking part
- Previous stroke
- Severe vision problems such as hemianopsia or neglect, or severe aphasia that prevents training
- Pregnant or breastfeeding women
- Implanted electronic devices that interfere with MRI, such as pacemakers or cochlear implants
- Psychiatric disorders, or severe heart, lung, liver or kidney disease
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 80 years old?
Source: NCT07553416, who can take part
Where in China
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07553416
- Record updated
- 28 April 2026
- Original description
This study aims to utilize non-invasive brain-computer interface technology in conjunction with mirror therapy to design a new paradigm for rehabilitation robots to induce compensatory movements on the healthy side in stroke patients, evaluate the potential rehabilitation value of this paradigm for patients with severely impaired motor areas on the affected side, explore the neural rehabilitation compensation mechanism, and provide more personalized rehabilitation treatment strategies for patients with post-stroke motor dysfunction.Read full original descriptionShow less
A Prospective, Randomized, Parallel-Controlled Clinical Study Protocol of Non-Invasive Brain Computer Interface Robot Based on Mirror Rehabilitation Theory in the Treatment of Upper Limb Motor Function Disorder After Stroke
This study aims to utilize non-invasive brain-computer interface technology in conjunction with mirror therapy to design a new paradigm for rehabilitation robots to induce compensatory movements on the healthy side in stroke patients, evaluate the potential rehabilitation value of this paradigm for patients with severely impaired motor areas on the affected side, explore the neural rehabilitation compensation mechanism, and provide more personalized rehabilitation treatment strategies for patients with post-stroke motor dysfunction.
Inclusion: Aged 30 to 80 years; Patients with unilateral upper limb motor dysfunction caused by primary ischemic/hemorrhagic stroke within 1 to 6 months prior to enrollment; Cerebral magnetic resonance diffusion-weighted imaging (DWI) at the time of onset indicating that the stroke lesion is limited to the unilateral basal ganglia region; Modified Rankin Scale (mRS) score of 0 to 2 before stroke onset; Fugl-Meyer Motor Function Assessment of Upper Extremities (FMA-UE) score of 10 to 42; Montreal Cognitive Assessment (MoCA) score > 18; Fugl-Meyer Balance Assessment score > 6; Normal binocular visual acuity or corrected visual acuity; Normal hearing and intact verbal comprehension ability; Provided written informed consent.
Exclusion: History of previous stroke; Undergoing major surgery within the past 30 days or planning to undergo major surgery within the next 90 days; Patients with other severe cardiovascular and cerebrovascular diseases and unstable vital signs; Patients with severe diseases of the lungs, liver, kidneys and other vital organs; Patients with limb movement impairment caused by diseases such as fractures and arthritis; A history of severe motor injury and/or surgical intervention of the affected upper limb, such as muscle tear, tendon rupture, rhabdomyolysis; Life expectancy of less than 1 year due to the underlying disease; History of drug or alcohol abuse, head trauma or central nervous system infection; current use of cognition-impairing medications such as psychoactive or sedative drugs; With definite psychiatric and psychological disorders, such as depression, anxiety disorder, obsessive-compulsive disorder, schizophrenia, autism, chronic sleep disorder, consciousness disorder, etc; Having implanted electronic devices in the body that interfere with magnetic resonance imaging (MRI), such as cochlear implants, cardiac pacemakers/defibrillators, drug delivery pumps; Patients with motor dysfunction caused by other etiologies, such as amyotrophic lateral sclerosis, myasthenia gravis, muscular dystrophy, hypokalemic periodic paralysis, spondylitis, arthritis, osteomyelitis, etc; Modified Ashworth Scale (MAS) score > 3; Patients unable to understand and cooperate with limb rehabilitation training due to factors such as severe aphasia; Presence of severe visual field defects or visual impairments (e.g., hemianopsia, hemispatial neglect, etc; Pregnant or lactating women; Poor compliance of the subject, their family members and caregivers, or inability to complete at least 12 months of follow-up as required by the study; Having been enrolled in other clinical studies that conflict with this study; Judged by the Indication Evaluation Committee as ineligible for or not falling within the scope of this study.